Publications

PUBLICATIONS

MiraKind is working to further identify ways to preserve health and prevent cancer for individuals with the KRAS-variant and other genetic variants like it.

Significant published research related to the KRAS-variant:

2021

Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population
M P Gallegos-Arreola, P M Garc√≠a Verd√≠n, M T Maga√Īa-Torres, L E Figuera, G M Z√ļ√Īiga-Gonz√°lez, M A Rosales-Reynoso, B C G√≥mez-Meda, A M Puebla-P√©rez Eur Rev Med Pharmacol Sci. 20Nov;25(21):6454-6464. PMID: 34787849

2020

Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population
Neda Farokhzad, Sayed Mostafa Hosseini, Houri Edalat, Morteza Sadeghi
Afr Health Sci. 2020 Sep;20(3):1299-1303. PMID: 33402978

2019

MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis
Morteza Gholami, Bagher Larijani, Farshad Sharifi, Shirin Hasani-Ranjbar, Reza Taslimi, Milad Bastami, Rasha Atlasi, Mahsa M Amoli, Cancer Med. 2019 Dec;8(17):7477-7499. doi: 10.1002/cam4.2600. PMID: 31637880

Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study
Thomas M D'Hooghe, Olga Grechukhina, SiHyun Cho, Amelie Fassbender, Dorien O, Dani√ęlle Peterse, Joanne Weidhaas, Hugh S Taylor, Gynecol Obstet Invest. 2019;84(6):575-582. doi:10.1159/000500626. Epub 2019 Jun 11 PMID: 31185482

Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers
Vianney Bastit, Nicolas Bon-Mardion, Jean-Michel Picquenot, Vinciane Rainville, Cristian Moldovan, Arnaud François, Agnès Loeb, Sébastien Thureau, Dorel Manu, Fabrice Jardin, Jean-Paul Marie, Fréderic Di Fiore, Florian Clatot
Eur Arch Otorhinolaryngol. 2019 Feb;276(2):541-550. doi: 10.1007/s00405-018-5235-6. PMID: 30523411

2017

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis
E K Morgen, H-J Lenz, D J Jonker, D Tu, G Milano, F Graziano, J Zalcberg, C S Karapetis, A Dobrovic, C J O'Callaghan, G Liu
Pharmacogenomics J. 2017 Dec;17(6):535-542. doi: 10.1038/tpj.2016.56. PMID: 27897268

KRAS Gene Polymorphisms and their Impact on Breast Cancer Risk in an Iranian Population
Sanaei S, Hashemi M, Eskandari E, Hashemi SM, Bahari G.
Asian Pac J Cancer Prev. 2017 May 1;18(5):1301-1305.
PMID: 28610418

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478. PMID: 28006059

2016

A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B.
J Cancer Res Clin Oncol. 2016 Sep 12.

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fern√°ndez-Mateos J, Seijas-Tamayo R, Mes√≠a R, Taberna M, Pastor Borgo√Ī√≥n M, P√©rez-Ruiz E, Adansa Klain JC, V√°zquez Fern√°ndez S, Del Barco Morillo E, Lozano A, Gonz√°lez Sarmiento R, Cruz-Hern√°ndez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).
Oral Oncol. 2016 Dec;63:38-43. doi: 10.1016/j.oraloncology.2016.10.006. Epub 2016 Nov 12. PMID: 27938998

A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells. 
Zhang S1, Hou C1, Li G1, Zhong Y1, Zhang J1, Guo X1, Li B2, Bi Z1, Shao M1.1., Int J Mol Med. 2016 Sep;38(3):919-26. doi: 10.3892/ijmm.2016.2661. Epub 2016 Jul 4.

The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
Gutiérrez-Malacatt H, Ayala-Sanchez M, Aquino-Ortega X, Dominguez-Rodriguez J, Martinez-Tovar A, Olarte-Carrillo I, Martinez-Hernandez A, C CC, Orozco L, Cordova EJ. Asian Pac J Cancer Prev. 2016;17(4):2265-70. PMID: 27221928, Free Article, Similar articles, Select item 26710843

KRAS polymorphisms are associated with survival of CRC in Chinese population.
Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH., Tumour Biol. 2016 Apr;37(4):4727-34. doi: 10.1007/s13277-015-4314-1. Epub 2015 Oct 29., PMID: 26515332, Similar articles, Select item 26162609

2015

Impact of KRAS variant rs61764370 on breast cancer morbidity.
Ustinova M, Daneberga Z, BńďrziŇÜa D, Nakazawa-MiklaŇ°evińća M, Maksimenko J, Gardovskis J, MiklaŇ°evińćs E., Exp Oncol. 2015 Dec;37(4):292-4., PMID: 26710843,¬†Similar articles,¬†Select item 26573509

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M., Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331., PMID: 26573509, Free PMC Article, Similar articles Select item 26515332

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N., Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10., PMID: 26162609, Similar articles, Select item 26077004

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P., Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11., PMID: 26077004, Free Article, Similar articles, Select item 25987236

Functional variants in CYP1B1, KRAS and MTHFR genes are associated with shorter telomere length in postmenopausal women.
Cerne JZ, Pohar-Perme M, Cerkovnik P, Gersak K, Novakovic S., Mech Ageing Dev. 2015 Jul;149:1-7. doi: 10.1016/j.mad.2015.05.003. Epub 2015 May 15., PMID: 2598723, Similar articles, Select item 25940428

Estrogen Withdrawal, Increased Breast Cancer Risk and the KRAS-variant.
McVeigh TP et al. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. PMID: 25961464  Free PMC Article Similar articles Select item 25940428

Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS, Shahbazi S, Moghaddam SA, Mahdian R., Reprod Sci. 2015 Jun;22(6):679-84. doi: 10.1177/1933719114556478. Epub 2014 Oct 30., PMID: 25361550, Free PMC Article, Similar articles, Select item 25183481

2014

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J., PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014., PMID: 24732316 Free PMC Article, Similar articles, Select item 23083368

The involvement of KRAS gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.
Ying HQ, Wang F, He BS, Pan YQ, Gao TY, Xu YQ, Li R, Deng QW, Sun HL, Wang SK., Onco Targets Ther. 2014 Aug 25;7:1487-96. doi: 10.2147/OTT.S65496. eCollection 2014., PMID: 25210463 Free PMC Article, Similar articles, Select item 25183481

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S., Clin Cancer Res. 2014 Sep 1;20(17):4499-510. doi: 10.1158/1078-0432.CCR-14-0348., PMID: 25183481 Free PMC Article, Similar articles, Select item 2511458

MicroRNA binding site polymorphisms as biomarkers in cancer management and research.
Cipollini M, Landi S, Gemignani F., Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review., PMID: 25114582, Free PMC Article, Similar articles, Select item 25081901

A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K, Duprez F, Ferdinande L, Mbah C, Rios-Velazquez E, Hoebers F, Praet M, Deron P, Bonte K, Speel EJ, Libbrecht L, De Neve W, Lambin P, Thierens H., Cancer Epidemiol. 2014 Oct;38(5):591-8. doi: 10.1016/j.canep.2014.07.008. Epub 2014 Aug 12., PMID: 25127693, Similar articles, Select item 24932237

SLC23A2-05 (rs4987219) and KRAS-LCS6 (rs61764370) polymorphisms in patients with squamous cell carcinoma of the head and neck.
Santiago MB, DE Lima Marson FA, Secolin R, Ribeiro JD, Lima CS, Bertuzzo CS., Oncol Lett. 2014 Jun;7(6):1803-1811. Epub 2014 Apr 3., PMID: 24932237 Free PMC Article, Similar articles, Select item 24890702

Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM, Christensen BC., Cancer Med. 2014 Oct;3(5):1385-95. doi: 10.1002/cam4.279. Epub 2014 Jun 2. Review., PMID: 24890702 Free PMC Article, Similar articles, Select item 24282149

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB., Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11., PMID: 24727325 Free PMC Article, Similar articles, Select item 23324806

2012

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH., BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534., PMID: 23167843 Free PMC Article, Similar articles, Select item 23010532

No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT, Nyholt DR, Painter JN, Chapman B, Kennedy S, Treloar SA, Zondervan KT, Montgomery GW., Hum Reprod. 2012 Dec;27(12):3616-21. doi: 10.1093/humrep/des329. Epub 2012 Sep 25., PMID: 23010532 Free PMC Article, Similar articles, Select item 22679560

KRAS-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M., Am J Cancer Res. 2012;2(3):298-308. Epub 2012 Apr 21., PMID: 22679560 Free PMC Article, Similar articles, Select item 22662244

KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter
Ryan BM, et al. Clin Cancer Res. 2012 Jun 15;18(12):3487-8; author reply 3489.

2011

MicroRNA signatures differentiate melanoma subtypes
Chan E. et al. Cell Cycle. 2011 Jun1:10(11):1845-52.

KRAS rs61764370 in Epithelial Ovarian Cancer-Letter
Joanne B. Weidhaas and Frank J. Slack. Clinical Cancer Research. Accepted May 31, 2011.

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, D√∂rk T, D√ľrst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O; GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M; HEBON Investigators, Heikkinen T, Hein R, H√łgdall C, H√łgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, L√°zaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A; SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA; Ovarian Cancer Association Consortium.,¬†Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.,¬†PMID: 21385923¬†Free PMC Article,¬†Similar articles,¬†Select item 20676756

2009

The BRCA1 3‚Äô-UTR: 5711√ĺ421T=T_5711√ĺ1286T=T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor
Malinee Pongsavee et al. GENETIC TESTING AND MOLECULAR BIOMARKERS. Volume 13, Number 3, 2009 Mary Ann Liebert, Inc. Pp. 307-317.

bottom-up-left-heavy-curve
arrow up to top